WEKO3
アイテム
{"_buckets": {"deposit": "d87d6c14-22cc-45b0-9509-1b60b4c0fa6e"}, "_deposit": {"created_by": 1, "id": "66013", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "66013"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00066013", "sets": ["29"]}, "author_link": ["650059", "650060", "650058", "650061"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2016-10-07", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. About 20% of GC is reported as HER2-overexpressed (HER2+), and trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2+ PMGC. Radioimmunotherapy (RIT), the internal radiotherapy using radioisotope (RI)-labeled cancer specific antibody, has huge advantage in targeting metastatic cancer. Recently, alpha-RIT, using alpha emitting RI, is getting higher attention, because the alpha particle has high cell cytotoxicity and its short range can prevent damages to untargeted tissues. Astatine 211 (\u003cSUP\u003e211\u003c/SUP\u003eAt) is one of the useful alpha-RI. In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with \u003cSUP\u003e211\u003c/SUP\u003eAt-trastuzumab against of HER2+ PMGC both in vitro and in vivo. We will discuss the possibility of alpha-RIT with \u003cSUP\u003e211\u003c/SUP\u003eAt-trastuzumab as a new effective therapeutic for HER2+ PMGC.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "第75回日本癌学会学術総会", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "李, 惠子"}], "nameIdentifiers": [{"nameIdentifier": "650058", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "長谷川, 純崇"}], "nameIdentifiers": [{"nameIdentifier": "650059", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "李 惠子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "650060", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "長谷川 純崇", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "650061", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/66013", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-11-09"}, "publish_date": "2016-11-09", "publish_status": "0", "recid": "66013", "relation": {}, "relation_version_is_last": true, "title": ["HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法"], "weko_shared_id": -1}
HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法
https://repo.qst.go.jp/records/66013
https://repo.qst.go.jp/records/66013902e5458-d640-498c-8039-767ef58e85c6
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-11-09 | |||||
タイトル | ||||||
タイトル | HER2高発現胃がん腹膜播種に対するα線放出核種211Atを用いた放射免疫療法 | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
李, 惠子
× 李, 惠子× 長谷川, 純崇× 李 惠子× 長谷川 純崇 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. About 20% of GC is reported as HER2-overexpressed (HER2+), and trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2+ PMGC. Radioimmunotherapy (RIT), the internal radiotherapy using radioisotope (RI)-labeled cancer specific antibody, has huge advantage in targeting metastatic cancer. Recently, alpha-RIT, using alpha emitting RI, is getting higher attention, because the alpha particle has high cell cytotoxicity and its short range can prevent damages to untargeted tissues. Astatine 211 (<SUP>211</SUP>At) is one of the useful alpha-RI. In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with <SUP>211</SUP>At-trastuzumab against of HER2+ PMGC both in vitro and in vivo. We will discuss the possibility of alpha-RIT with <SUP>211</SUP>At-trastuzumab as a new effective therapeutic for HER2+ PMGC. | |||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 第75回日本癌学会学術総会 | |||||
発表年月日 | ||||||
日付 | 2016-10-07 | |||||
日付タイプ | Issued |